Figure 1From: Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survivalStudy overview of patients and samples at the different time points. Bone marrow (BM) aspiration and peripheral blood (PB) sampling performed pretreatment (BM1 and PB1), at surgery (BM2 and PB2), and 12 months after start of neoadjuvant treatment (BM3 and PB3). NACT, neoadjuvant chemotherapy.Back to article page